Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (AvPAK)
FDA approved AvPAK's original application for pregabalin, enabling the generic version to enter the market.
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for pregabalin (generic) submitted by Rising Pharma Holdings, Inc., authorizing its market authorizati…
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic pregabalin under ANDA207623 (original application), providing a generic version of pregabalin.
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' original ANDA for pregabalin, enabling a generic version of pregabalin to be marketed. The approva…
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's original ANDA for pregabalin, a generic version of Lyrica, for use in the United States. Th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures [Phase 3]
A Phase 3 long-term safety and tolerability study of lacosamide as monotherapy in adults with partial-onset seizures has completed with resu…
-
FDA approval · 2019-06-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The supplement likely updates the product labeling or…
-
FDA approval · 2019-05-30FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for FYCOMPA (perampanel), expanding the drug's labeled uses.
-
FDA approval · 2019-05-23FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Div of Pfizer Inc, indicating an approved modificat…
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA granted approval of a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., to update or expand its labeling.
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The approval represents a modification to the product…
-
FDA approval · 2018-11-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., signaling an update to its labeling and indication.
-
FDA approval · 2018-11-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., updating the labeling for this antiepileptic drug.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. [Phase 3]
A Phase 3 trial evaluated pregabalin as add-on therapy in pediatric subjects under 4 with partial onset seizures; results completed with pos…
-
FDA approval · 2018-05-10FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for BRIVIACT (brivaracetam) submitted by UCB, Inc.
-
FDA approval · 2018-05-10FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc., which updates the product labeling.
-
FDA approval · 2018-05-10FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for BRIVIACT (brivaracetam) submitted by UCB, Inc.
-
FDA approval · 2018-03-22FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Trileptal (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2018-02-26Clinical Trial Update: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) [Phase 3]
Phase 3 long-term safety study of retigabine IR as adjunctive therapy for adults with partial-onset seizures has completed with results post…
-
FDA approval · 2017-11-03FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., authorizing changes included in the supplemental sub…
-
FDA approval · 2017-11-03FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2017-10-26FDA Approved: GABAPENTIN — Original Application (Precision Dose, Inc.)
FDA approved the original application for gabapentin from Precision Dose, Inc., establishing a generic version of the anticonvulsant.
-
FDA approval · 2017-10-24FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, expanding the product to an extended-release formulation…
-
FDA approval · 2017-10-11FDA Approved: LYRICA CR — Original Application (Viatris Specialty LLC)
FDA approves LYRICA CR (pregabalin) under an Original Application for an extended-release formulation of pregabalin.